Skip to main content
    B

    Biogen Inc (BIIB)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $250.79
    -0.86 (-0.34%)

    Market Cap: $37.20B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Biogen Inc (BIIB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Biogen (BIIB) has a market cap of $37.20B and an enterprise value of $43.59B. Its return on invested capital of 1.27% compares with a 7.58% median across 10 similar companies. Its trailing P/E of 21.3x is above its 10-year median of 12.4x.

    Total Valuation

    Enterprise value is 17.17% above the market cap, as debt exceeds cash.

    Market Cap$37.20B
    Enterprise Value$43.59B
    Latest price (Nov 17, 2026)$250.79

    Key Dates

    The next earnings report is expected on Feb 4, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 4, 2027 (expected)
    Last Earnings DateOct 28, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.07% in the quarter ended Sep 30, 2026 and grew 0.72% a year over 2 years.

    Shares Outstanding147.80M
    Shares Change (YoY)+0.82%
    Shares Change (QoQ)+0.07%
    Share Count Growth (2Y CAGR)+0.72%

    Valuation Ratios

    Sales and book value multiples are 3.6x and 2.0x. Its year-end P/E ranged from 7.5x to 17.2x from 2016 to 2025.

    P/E Ratio21.3x
    Forward P/E19.6x
    P/S Ratio3.6x
    Forward P/S3.5x
    P/B Ratio2.0x
    P/FCF Ratio17.9x
    P/OCF Ratio16.6x
    PEG Ratio2.9

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 22.9x EBITDA and 21.0x free cash flow.

    EV / Earnings130.4x
    EV / Sales4.2x
    EV / EBITDA22.9x
    EV / FCF21.0x

    Price Statistics

    The stock is up 49.68% over 52 weeks and trades 6.84% above its 50-day average.

    Beta (1Y)0.39
    52-Week Change+49.68%
    1-Month Change+7.41%
    3-Month Change+13.19%
    6-Month Change+31.61%
    5-Year Change-4.90%
    10-Year Change-9.48%
    Total Return (1Y)+49.68%
    Total Return (3Y CAGR)+3.23%
    Total Return (5Y CAGR)-0.47%
    Return vs SPY (1Y)+36.99%
    Max Drawdown (1Y)-14.34%
    Max Drawdown (3Y)-57.65%
    Sharpe Ratio (1Y)1.17
    Correlation with SPY (1Y)0.16
    50-Day Average$234.73
    200-Day Average$205.87
    52-Week Range$160.36 to $261.00
    RSI (14 Days)56.0
    Average Volume (20 Days)1.20M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.95x current liabilities, and total debt is 0.41x shareholder equity.

    Current Ratio1.95x
    Quick Ratio1.37x
    Debt / Equity0.41x
    Debt / EBITDA4.06x
    Debt / FCF3.71x

    Returns and Efficiency

    Return on invested capital is 1.27% over the last 12 months, against a 5-year average of 8.41%.

    Return on Equity (ROE)1.77%
    Return on Assets (ROA)1.04%
    Return on Invested Capital (ROIC)1.27%
    ROE (5Y Average)12.53%
    ROA (5Y Average)6.77%
    ROIC (5Y Average)8.41%
    Asset Turnover0.34x
    Inventory Turnover1.16x
    Receivables Turnover4.31x
    Cash Conversion Cycle342 days

    Taxes

    Income tax took 21.93% of pretax income over the last 12 months.

    Income Tax (TTM)$97.60M
    Effective Tax Rate21.93%

    Scores

    BIIB has an Altman Z-Score of 3.11, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score3.11
    Altman Z ZoneSafe
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $10.30B over the last 12 months is up 2.30% from the 12 months before.

    Revenue$10.30B
    Revenue Growth (YoY)+2.30%
    Gross Profit$7.62B
    Operating Income$431.90M
    Pretax Income$445.10M
    Net Income$334.30M
    EBITDA$1.90B
    Reported EPS (TTM)$11.78

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 59.03% of the $32.05B in total assets.

    Cash and Equivalents$1.30B
    Total Debt$7.69B
    Net Debt$6.39B
    Net Debt Per Share$43.22
    Working Capital$3.69B
    Shareholder Equity$18.92B
    Book Value Per Share$128.03
    Tangible Book Value-$1.45B
    Total Assets$32.05B
    Total Liabilities$13.13B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $176.40M of capital spending, operating cash flow left $2.07B of free cash flow.

    Operating Cash Flow$2.25B
    Capital Expenditures$176.40M
    Free Cash Flow$2.07B
    FCF Per Share$14.01
    Depreciation and Amortization$1.46B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 4.19%, against a 5-year average of 21.75%.

    Gross Margin73.96%
    Operating Margin4.19%
    Pretax Margin4.32%
    Net Margin3.25%
    EBITDA Margin18.42%
    FCF Margin20.11%
    Gross Margin (5Y Average)76.89%
    Operating Margin (5Y Average)21.75%
    Net Margin (5Y Average)17.32%

    Growth

    Revenue fell 0.94% a year over 3 years, and EPS 4.74% a year.

    Revenue Growth (3Y CAGR)-0.94%
    Revenue Growth (5Y CAGR)-5.96%
    EPS Growth (3Y CAGR)-4.74%
    EPS Growth (5Y CAGR)-14.17%
    FCF Growth (3Y CAGR)+21.48%
    FCF Growth (5Y CAGR)-11.63%
    Operating Income Growth (3Y CAGR)-23.55%
    Book Value Per Share Growth (2Y CAGR)+10.69%
    Tangible Book Per Share Growth (2Y CAGR)+243.95%

    Revenue and profit by year

    Dividends and Yields

    BIIB does not pay a dividend. Its free cash flow yield is 5.59%.

    Earnings Yield4.69%
    FCF Yield5.59%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 3-for-1 forward split on Jan 18, 2001.

    Last Split DateJan 18, 2001
    Split TypeForward split
    Split Ratio3:1

    Peer Position

    Against 8 similar companies, BIIB has the 3rd highest P/E.

    P/E Ratio21.3x vs 14.4x median
    P/S Ratio3.6x vs 4.0x median
    ROIC1.27% vs 7.58% median
    Revenue Growth (Trailing 4 Quarters, YoY)+2.30% vs +6.54% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 4.38% and EPS growth at 3.12% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+4.38%
    EPS Growth Forecast (2Y CAGR)+3.12%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BIIB

    What is BIIB's market cap?

    Biogen has a market cap of $37.20B. Its enterprise value, which adds debt and subtracts cash, is $43.59B.

    What is BIIB's P/E ratio?

    Biogen has a trailing P/E ratio of 21.3x and a forward P/E of 19.6x.

    How many shares of BIIB are outstanding?

    Biogen has 147.80M shares outstanding. The count is up 0.82% from a year earlier.

    Does BIIB pay a dividend?

    No. Biogen does not pay a dividend.

    How much debt does BIIB have?

    Biogen has $7.69B of total debt and $1.30B of cash and equivalents, a net debt position of $6.39B.